Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity.
CD137
Fc-receptors
glycosylation
therapeutic antibody
urelumab
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
06
2022
accepted:
30
08
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
Checkpoint control and immunomodulatory antibodies have become important tools for modulating tumor or self-reactive immune responses. A major issue preventing to make full use of the potential of these immunomodulatory antibodies are the severe side-effects, ranging from systemic cytokine release syndrome to organ-specific toxicities. The IgG Fc-portion has been demonstrated to contribute to both, the desired as well as the undesired antibody activities of checkpoint control and immunomodulatory antibodies
Identifiants
pubmed: 36248847
doi: 10.3389/fimmu.2022.970290
pmc: PMC9558126
doi:
Substances chimiques
Antibodies, Monoclonal
0
Immunoglobulin G
0
Receptors, IgG
0
urelumab
230902QLLC
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
970290Informations de copyright
Copyright © 2022 Reitinger, Ipsen-Escobedo, Hornung, Heger, Dudziak, Lux and Nimmerjahn.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
EMBO Mol Med. 2022 Jan 11;14(1):e14182
pubmed: 34842342
Front Immunol. 2018 Oct 08;9:2306
pubmed: 30349540
Cell Rep. 2014 Apr 10;7(1):236-48
pubmed: 24685130
Cancer Cell. 2015 Oct 12;28(4):543
pubmed: 28854351
Nat Commun. 2019 May 20;10(1):2141
pubmed: 31105267
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):11048-11053
pubmed: 30297432
Cancer Treat Rev. 2017 Jun;57:36-49
pubmed: 28550712
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
J Immunol. 1995 Oct 1;155(7):3360-7
pubmed: 7561030
Cancer Immunol Immunother. 2010 Sep;59(9):1367-77
pubmed: 20480365
Cancer Cell. 2015 Jan 12;27(1):10-1
pubmed: 25584890
J Immunol. 2002 Feb 1;168(3):1457-65
pubmed: 11801689
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
Cell Rep. 2015 Oct 20;13(3):610-620
pubmed: 26456831
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15005-9
pubmed: 18815375
Cell Rep. 2015 Dec 22;13(11):2376-2385
pubmed: 26670049
J Exp Med. 2013 Aug 26;210(9):1685-93
pubmed: 23897982
J Immunol. 2013 Apr 15;190(8):4315-23
pubmed: 23509345
Clin Cancer Res. 2017 Apr 15;23(8):1929-1936
pubmed: 27756788
Cancer Cell. 2015 Jan 12;27(1):138-48
pubmed: 25500122
Cell Mol Immunol. 2004 Feb;1(1):31-6
pubmed: 16212918
J Clin Invest. 2013 Jun;123(6):2447-63
pubmed: 23728179
Immunity. 2018 Nov 20;49(5):958-970.e7
pubmed: 30446386
J Immunol. 2011 Aug 15;187(4):1754-63
pubmed: 21742972
J Exp Med. 1929 Nov 30;50(6):809-23
pubmed: 19869667
MAbs. 2019 Feb/Mar;11(2):219-238
pubmed: 30516432
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Immunity. 2016 Aug 16;45(2):225-6
pubmed: 27533005
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18772-7
pubmed: 22065769
Science. 2011 Aug 19;333(6045):1030-4
pubmed: 21852502
Mol Cancer Ther. 2020 Apr;19(4):1040-1051
pubmed: 31974274
J Clin Immunol. 2013 Jan;33 Suppl 1:S4-8
pubmed: 22948744
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Proc Natl Acad Sci U S A. 1989 Mar;86(6):1963-7
pubmed: 2784565
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
J Immunol. 1997 Mar 15;158(6):2600-9
pubmed: 9058792